Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory CLL/SLL: Additional patients and extended follow-up from the phase 1/2 BRUIN study
    Meeting Abstract

    Mato, A. R.; Woyach, J. A.; Brown, J. R.; Ghia, P.; Patel, K.; Eyre, T. A.; Munir, T.; Lech-Maranda, E.; Lamanna, N.; Tam, C. S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • NX-2127-001, first-in-human trial of NX-2127, a Bruton's tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell malignancies
    Meeting Abstract

    Mato, A. R.; Wierda, W. G.; Ai, W. Z.; Flinn, I. W.; Tees, M.; Patel, M. R.; Patel, K.; O'Brien, S.; Bond, D. A.; Roeker, L. E.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with newly diagnosed and relapsed acute leukemia
    Meeting Abstract

    Nath, K.; Lee, J.; Elko, T. A.; Levy, L.; Preston, E.; Devlin, S. M.; Ponce, D. M.; Lin, R. J.; Shaffer, B. C.; Cho, C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Single cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia
    Meeting Abstract

    Robinson, T.; Bowman, R. L.; Persaud, S.; Liu, Y.; Gao, Q.; Zhang, J. P.; Sun, X.; Sciambi, A.; Llanso, A.; Famulare, C.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • MGTA-117, an anti-CD117 antibody-drug conjugated with amanitin, in participants with relapsed/refractory adult acute myeloid leukemia (AML) and myelodysplasia with excess blasts (MDS-EB): Safety, pharmacokinetics and pharmacodynamics initial findings from a phase 1/2 study
    Meeting Abstract

    Westervelt, P.; Kebriaei, P.; Juckett, M.; Artz, A. S.; Chan, O.; McCarthy, P. L.; Farag, S. S.; Singh, A. K.; Stein, E.; Humphrey, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures
    Meeting Abstract

    Ziccheddu, B.; Diamond, B.; Maclachlan, K. H.; Taylor, J.; Boyle, E. M.; Arango Ossa, J. E.; Jacob, J.; Affer, M.; Totiger, T. M.; Coffey, D.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A risk-adapted study to assess the efficacy of enasidenib and subsequent response-driven addition of azacitidine for newly diagnosed IDH2-mutant AML patients: 3-year follow-up
    Meeting Abstract

    Stein, E.; Cai, S. F.; Huang, Y.; Dunbar, A.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W. G.; Schiller, G. J.; Olin, R. L.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Kinase dead BTK mutations confer resistance to covalent and noncovalent BTK inhibitors but are susceptible to clinical stage BTK degraders
    Meeting Abstract

    Montoya, S.; Bourcier, J.; Thompson, M. C.; Noviski, M.; Tan, M.; Wang, E.; Mi, X.; Brathaban, N.; Risso, C. B.; Tsai, D.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Three-year update from the optic trial: A dose-optimization study of 3 starting doses of ponatinib
    Meeting Abstract

    Cortes, J. E.; Deininger, M. W.; Lomaia, E.; Moiraghi, B.; Sutton, M. U.; Pavlovsky, C.; Chuah, C.; Sacha, T.; Lipton, J. H.; McCloskey, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Clinical benefit associated with biomarker changes indicative of disease modification in patients with myelofibrosis treated with the BET inhibitor pelabresib as monotherapy or in combination with ruxolitinib
    Meeting Abstract

    Scandura, J.; Verstovsek, S.; Kremyanskaya, M.; Talpaz, M.; Rampal, R. K.; Vannucchi, A.; Gupta, V.; Palandri, F.; Patriarca, A.; Bose, P.; more...
    Blood (2022)

    Fulltext@MSK | Save